Priority Reviews At US FDA: From Third Quarter Spikes To A Third Quarter Trough
Executive Summary
Priority review announcements saw significant dip in third quarter 2018, while they usually experience a spike during the period; breakthrough therapy designations remained in double digits.
You may also be interested in...
Keeping Track: An Approval For Ajovy, A CRL For Ruconest, And Some Submissions from J&J
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
The latest drug development news and highlights from our US FDA Performance Tracker.
Breakthrough Therapy Designations Set Quarterly Record
US FDA granted designations for several products based on late-stage data; with at least 19 breakthrough therapy designations, five-year-old program sets another record in first quarter of 2018.